Humacyte (NASDAQ:HUMA) Trading Down 5% – Should You Sell?

Shares of Humacyte, Inc. (NASDAQ:HUMA) traded down 5% on Monday . The company traded as low as $5.11 and last traded at $5.12. 1,134,125 shares changed hands during trading, a decline of 51% from the average session volume of 2,332,447 shares. The stock had previously closed at $5.39.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of Humacyte in a research report on Friday, October 18th. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Finally, TD Cowen reissued a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $10.00.

Humacyte Trading Down 5.9 %

The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $605.10 million, a PE ratio of -4.15 and a beta of 1.47. The business has a 50 day moving average price of $5.57 and a 200-day moving average price of $6.10.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Analysts expect that Humacyte, Inc. will post -1.09 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Laura E. Niklason sold 277,090 shares of Humacyte stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the completion of the transaction, the chief executive officer now directly owns 4,029,374 shares of the company’s stock, valued at approximately $26,070,049.78. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the sale, the director now owns 3,677,262 shares of the company’s stock, valued at $23,350,613.70. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Laura E. Niklason sold 277,090 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $6.47, for a total value of $1,792,772.30. Following the transaction, the chief executive officer now owns 4,029,374 shares in the company, valued at $26,070,049.78. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock worth $6,869,996 in the last quarter. Company insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Several institutional investors have recently made changes to their positions in the stock. Concurrent Investment Advisors LLC acquired a new stake in Humacyte in the 3rd quarter valued at $75,000. China Universal Asset Management Co. Ltd. boosted its stake in Humacyte by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock valued at $125,000 after acquiring an additional 8,965 shares during the period. Private Advisor Group LLC increased its position in Humacyte by 1.8% in the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock worth $2,030,000 after buying an additional 6,510 shares during the period. Wealth Effects LLC bought a new stake in Humacyte in the 3rd quarter valued at about $349,000. Finally, SG Americas Securities LLC acquired a new position in Humacyte during the 3rd quarter valued at about $174,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.